We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




AI Tool Combines Data from Medical Images with Text to Predict Cancer Prognoses

By LabMedica International staff writers
Posted on 10 Jan 2025

The integration of visual data (such as microscopic and X-ray images, CT and MRI scans) with textual information (like exam notes and communications between doctors of different specialties) is a crucial aspect of cancer care. More...

While artificial intelligence (AI) tools have been increasingly employed in clinical settings, their primary application has been in diagnostics rather than prognosis. AI aids doctors in reviewing images and detecting disease-related anomalies, such as abnormally shaped cells, but developing computerized models that can combine various types of data has been a challenge. One of the difficulties is the need to train these models with large amounts of labeled and paired data, like a microscope slide showing a cancerous tumor alongside the clinical notes of the patient from whom the tumor was obtained. However, curated and annotated datasets are often scarce. Researchers have now developed an AI model capable of integrating both visual and textual data. After training on 50 million medical images of standard pathology slides and more than 1 billion pathology-related texts, the model surpassed traditional methods in its ability to predict the prognoses of thousands of cancer patients, identify individuals with lung or gastroesophageal cancers likely to benefit from immunotherapy and pinpoint melanoma patients most at risk of experiencing a recurrence.

The model, named MUSK (multimodal transformer with unified mask modeling), was developed by researchers at Stanford Medicine (Stanford, CA, USA). MUSK marks a significant departure from the typical use of AI in clinical settings, and the researchers believe it has the potential to transform how AI can guide patient care. In AI terminology, MUSK is considered a foundation model. Foundation models, which are pretrained on large datasets, can be further fine-tuned with additional training to handle specific tasks. Since MUSK was designed to utilize unpaired multimodal data that does not meet the traditional requirements for training AI, it can leverage a much larger pool of data for its initial learning phase. As a result, subsequent training only requires smaller, more specialized datasets. Essentially, MUSK is a ready-to-use tool that doctors can customize to answer specific clinical questions.

To develop MUSK, the researchers gathered microscopic tissue slides, pathology reports, and follow-up data (including patient outcomes) from The Cancer Genome Atlas, a national database, for individuals with 16 major cancer types, such as breast, lung, colorectal, pancreatic, kidney, bladder, and head and neck cancers. This data was used to train MUSK to predict disease-specific survival or the percentage of patients who have not died from a specific disease within a given time frame. According to the study, published in Nature, MUSK accurately predicted disease-specific survival for all cancer types 75% of the time. In comparison, traditional predictions based on a person’s cancer stage and other clinical risk factors were correct 64% of the time. In another example, MUSK was trained to analyze extensive data to predict which patients with lung cancer or cancers of the gastric and esophageal tracts are most likely to benefit from immunotherapy.

For non-small cell lung cancer, MUSK identified patients who responded well to immunotherapy approximately 77% of the time. In contrast, the conventional method of predicting immunotherapy response based on PD-L1 expression was correct only 61% of the time. Similarly, when the researchers trained MUSK to identify melanoma patients at high risk of relapse within five years after initial treatment, the model was accurate about 83% of the time, which is roughly 12% more accurate than other foundation models.

“MUSK can accurately predict the prognoses of people with many different kinds and stages of cancer,” said Ruijiang Li, MD, an associate professor of radiation oncology. “We designed MUSK because, in clinical practice, physicians never rely on just one type of data to make clinical decisions. We wanted to leverage multiple types of data to gain more insight and get more precise predictions about patient outcomes.”

“What’s unique about MUSK is the ability to incorporate unpaired multimodal data into pretraining, which substantially increases the scale of data compared with paired data required by other models,” added Li.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
New
Portable POCT Blood Gas Analyzer
BD100
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.